InvestSMART

Wellnex Life Limited (ASX:WNX)

ALERT: Price-sensitive ASX Announcement for WNX
Current share price for WNX : $0.092 0.037 (67.27%)+
Announcement
Release
6 Aug 2026 4:35PM
Price at Release
$0.055
Full Release
download
Summary
Wellnex Life Limited has entered into a binding agreement to sell its Pain Away business and assets to Mentholatum Australasia Pty Ltd for up to A$21.3 million. This transaction includes an upfront payment of A$19.8 million and an earn-out of up to A$1.5 million, contingent on certain performance metrics over the following year. The sale aligns with Wellnex Life's strategic plan to repay its debt, bolster its balance sheet, and focus on its core consumer healthcare and contract manufacturing operations. The completion of the transaction is conditional upon shareholder approval and is anticipated to occur shortly after the approval is obtained, aiming for a date on or shortly after 8 September 2026.
Key Points
  • Wellnex Life to sell Pain Away for up to A$21.3 million.
  • Transaction includes A$19.8 million upfront and A$1.5 million earn-out.
  • Sale proceeds will be used to repay Wellnex Life's debt and support growth.
  • Shareholder approval required for transaction completion.
  • Transaction expected to complete shortly after 8 September 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.